NasdaqCM - Nasdaq Real Time Price USD

Heron Therapeutics, Inc. (HRTX)

1.5300

-0.0400

(-2.55%)

At close: December 19 at 4:00:02 PM EST

Exploring Three High Growth Tech Stocks In The United States

Over the last 7 days, the United States market has remained flat, yet it is up 30% over the past year with earnings forecasted to grow by 15% annually. In this context of robust growth potential, identifying high growth tech stocks that align with these positive trends can be key for investors seeking opportunities in an evolving market landscape.

Simply Wall St. 8 days ago

AUPH

NBIX

HRTX
-2.55%
U.S. District Court Upholds Validity of CINVANTI® Patents

Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the U.S. District Court for the District of Delaware ruled in Heron's favor in the Company's patent litigation against Fresenius Kabi USA, LLC with respect to CINVANTI® (aprepitant) injectable emulsion. The district court found that Heron's U.S. Patent Nos. 9,561,229 and 9,974,794, which expire in 2035, are valid and would be infringed by Fresenius' proposed generic

PR Newswire 16 days ago

HRTX
-2.55%
Heron Therapeutics Inc (HRTX) Q3 2024 Earnings Call Highlights

Heron Therapeutics Inc reports increase in gross profit margin.

GuruFocus.com last month

HRTX
-2.55%
Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks last month

HRTX
-2.55%
Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 0% and 9.86%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

HRTX
-2.55%
Heron Therapeutics: Q3 Earnings Snapshot

SAN DIEGO (AP) — Heron Therapeutics Inc. HRTX) on Tuesday reported a loss of $4.8 million in its third quarter. On a per-share basis, the San Diego-based company said it had a loss of 3 cents.

Associated Press Finance last month

HRTX
-2.55%
Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance

Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three and nine months ended September 30, 2024, and highlighted recent corporate updates.

PR Newswire last month

HRTX
-2.55%
Unveiling Heron Therapeutics (HRTX) Q3 Outlook: Wall Street Estimates for Key Metrics

Evaluate the expected performance of Heron Therapeutics (HRTX) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Zacks last month

HRTX
-2.55%
Positive Signs As Multiple Insiders Buy Heron Therapeutics Stock

It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...

Simply Wall St. last month

HRTX
-2.55%
Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, announced today the appointment of Michael Kaseta to its Board of Directors. Mr. Kaseta has an extensive background spanning corporate finance, business strategy, and the commercialization of biopharma products in large pharmaceutical companies and small biotech companies.

PR Newswire last month

HRTX
-2.55%
Journey Medical (DERM) Soars 7.3%: Is Further Upside Left in the Stock?

Journey Medical (DERM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks last month

DERM

HRTX
-2.55%
Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024

Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Tuesday, November 12, 2024, at 8:00 a.m. ET to report third quarter 2024 financial results and discuss recent business highlights.

PR Newswire last month

HRTX
-2.55%
Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids

Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today reaffirmed the Company's ability to supply CINVANTI® (aprepitant) injectable emulsion and SUSTOL® (granisetron) extended-release injection for Chemotherapy Induced Nausea and Vomiting ("CINV") prevention and APONVIE® for Postoperative Nausea and Vomiting ("PONV") prevention given the temporary shortage of intravenous ("IV") fluids which is expected as the result of Hurricane Helene

PR Newswire 2 months ago

HRTX
-2.55%
Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Path To Profitability

We feel now is a pretty good time to analyse Heron Therapeutics, Inc.'s ( NASDAQ:HRTX ) business as it appears the...

Simply Wall St. 2 months ago

HRTX
-2.55%
Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")

Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the U.S. Food and Drug Administration (the "FDA") has approved the Company's Prior Approval Supplement Application for ZYNRELEF® (bupivacaine and meloxicam) extended-release solution VAN.

PR Newswire 2 months ago

HRTX
-2.55%
Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced today the appointment of Brett Fleshman as Chief Business Officer. Mr. Fleshman will contribute his 25 years of experience in corporate and business development, commercial strategy, and marketing of pharmaceuticals, biologics, and surgical devices to the management

PR Newswire 3 months ago

HRTX
-2.55%
Heron Therapeutics Second Quarter 2024 Earnings: EPS Misses Expectations

Heron Therapeutics ( NASDAQ:HRTX ) Second Quarter 2024 Results Key Financial Results Revenue: US$36.0m (up 13% from 2Q...

Simply Wall St. 4 months ago

HRTX
-2.55%
Heron Therapeutics (HRTX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Heron Therapeutics (HRTX) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks 4 months ago

HRTX
-2.55%
Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue Estimates

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -50% and 1.91%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 4 months ago

HRTX
-2.55%
Heron Therapeutics: Q2 Earnings Snapshot

SAN DIEGO (AP) — Heron Therapeutics Inc. HRTX) on Tuesday reported a loss of $9.2 million in its second quarter. On a per-share basis, the San Diego-based company said it had a loss of 6 cents.

Associated Press Finance 4 months ago

HRTX
-2.55%

Performance Overview

Return	HRTX	S&P 500
YTD	-10.00%	+23.00%
1-Year	-12.07%	+23.76%
3-Year	-84.15%	+26.98%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Heron Therapeutics, Inc. (HRTX)

Exploring Three High Growth Tech Stocks In The United States

U.S. District Court Upholds Validity of CINVANTI® Patents

Heron Therapeutics Inc (HRTX) Q3 2024 Earnings Call Highlights

Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates

Heron Therapeutics: Q3 Earnings Snapshot

Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance

Unveiling Heron Therapeutics (HRTX) Q3 Outlook: Wall Street Estimates for Key Metrics

Positive Signs As Multiple Insiders Buy Heron Therapeutics Stock

Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors

Journey Medical (DERM) Soars 7.3%: Is Further Upside Left in the Stock?

Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024

Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids

Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Path To Profitability

Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")

Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer

Heron Therapeutics Second Quarter 2024 Earnings: EPS Misses Expectations

Heron Therapeutics (HRTX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue Estimates

Heron Therapeutics: Q2 Earnings Snapshot

Performance Overview